Form 4: Teva CFO Kalif Awarded 141,478 Restricted Share Units

Teva Pharmaceutical Industries Ltd.'s EVP and CFO, Eliyahu Sharon Kalif, was granted 141,478 restricted share units following the satisfaction of performance criteria.

Summary

• Eliyahu Sharon Kalif, EVP and Chief Financial Officer of Teva Pharmaceutical Industries Ltd. (TEVA), acquired 141,478 Restricted Share Units (RSUs).
• These RSUs were granted on January 27, 2026, at a price of $0 per unit.
• The grant resulted from the satisfaction of performance criteria related to previously issued performance share units.
• Each RSU represents a contingent right to receive one ordinary share or its cash equivalent, at the discretion of the Human Resources and Compensation Committee.
• The RSUs are subject to time-based vesting and are scheduled to vest on March 3, 2026.
• Following this transaction, Mr. Kalif beneficially owns 141,478 derivative securities (RSUs).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive event, reflecting the achievement of performance targets by a key executive and reinforcing alignment with shareholder interests through equity compensation.

Positives

• The grant of 141,478 Restricted Share Units to the CFO indicates successful achievement of performance criteria, aligning management incentives with shareholder interests.
• The vesting schedule through March 3, 2026, promotes retention of key executive talent.

Negatives

• No direct negatives are apparent from this Form 4 filing, which primarily reports an executive compensation event.

Future Outlook

The filing indicates a future vesting event for the granted Restricted Share Units on March 3, 2026, contingent on continued employment and time-based criteria.

Industry Context

StockSavvy.ai notes that equity grants like Restricted Share Units are a standard component of executive compensation packages in the pharmaceutical industry, designed to align executive incentives with long-term company performance and shareholder value. This grant to Teva's CFO is consistent with common practices among peer companies.

Comparison to Industry Standards

• The grant of performance-based equity awards, such as RSUs derived from performance share units, is a common practice in the pharmaceutical industry, aligning with compensation strategies seen at companies like Pfizer, Johnson & Johnson, and Novartis.
• The vesting period, extending to March 3, 2026, is typical for executive retention and long-term incentive plans across major pharmaceutical firms.
• The size of the grant (141,478 units) would need to be evaluated against the CFO's overall compensation package and company size relative to peers to determine if it is within industry norms, but the mechanism itself is standard.

Stakeholder Impact

• Shareholders: The grant aligns the CFO's interests with shareholders by tying a portion of compensation to company performance and future share value.
• Employees: May signal a stable executive team and a commitment to performance-based incentives.

Next Steps

• The Restricted Share Units are scheduled to vest on March 3, 2026, subject to time-based vesting conditions.

Key Dates

Recommendation

This Form 4 filing reports a routine executive compensation event (an RSU grant) that is generally expected and does not provide new material information that would significantly alter the investment thesis for Teva. While it indicates performance achievement and executive retention, it's not a catalyst for a "buy" or "sell" recommendation on its own. Investors should continue to hold based on broader company fundamentals and market conditions.

Keywords

Teva Pharmaceutical Industries, TEVA, Eliyahu Sharon Kalif, CFO, Restricted Share Units, RSU, Executive Compensation, Insider Transaction, Form 4, Performance Share Units, Equity Grant